The FDA announced it has approved fezolinetant for the treatment of moderate to severe hot flashes due to menopause. Fezolinetant (Veozah, Astellas Pharma) is an oral medication. It is the first neurokinin 3 receptor antagonist approved by the FDA for treatment of moderate to severe vasomotor symptoms, according to an FDA press release. This medication is not a hormone; fezolinetant binds